History

HOME>Company>History

Opening the era of development

as a specialized pharmaceutical company

Global TAEJOON's History

  • Established in 1978, Taejoon Pharmaceutical Co., Ltd. (“Taejoon”) has become a leading specialty pharmaceutical company in ophthalmology, gastroenterology, and radiology through the efforts to create a healthy world and R&D focus.
  • With a vision to become a company which respects and enhances the happiness of human life, Taejoon has established a mid and long-term goal to leaf forward to be the best R&D focused specialty pharmaceutical company in the world.
2020's
2010's
2000's
1990's
1980's
1970's
  • 2026
    • 02. Launched Korea’s first 0.05% Atropine Sulfate product, “MYOTECTO 0.05% / 0.1%”
  • 2025
    • 07. Launched Diquaday Eye drop 5%, promoting mucin and tear secretion
    • 05. Launched Coolprep Gold Powrder, a bowel cleansing with 0.8 L formulation plus simethicone
    • 01. Launched SUPREP mini S tablet for bowel cleansing
  • 2024
    • 11. Launched Infresh-F Eye Drops 1.5%, a high-concentration CMC dry eye treatment
    • 10. Launched OCUAREDSTU PLUS
    • 06. Re-certified as an Innovative Pharmaceutical Company
    • 06. Launched OCUAREDSTUG
  • 2023
    • 05. Launched SUPREP mini tablet for bowel cleansing
    • 01. Launched Lamina-G Chewable Tab. 200mg
  • 2022
    • 02. Launched IOBRIX INJ 270, IOBRIX INJ 320
  • 2021
    • 11. Obtained recertification as an innovative pharmaceutial company
    • 06. 'Awarded 'ISO 37001 Anti-bribery management system' certification
    • 02. Launched Alymus Ophthalmic Suspension for a treatment of Springtime keratoconjunctivitis with large papillary proliferation on eyelid conjunctiva
  • 2020
    • 10. Received Distinguished Service Medal Award (Korean Red Cross)
  • 2019
    • 10. Released Gadobrix 15 mL
    • 04. Released incrementally modified drug based on PEG+ Asc for bowel cleansing (CleanViewAL Powder)
  • 2018
    • 11. Conducted Korea's first glaucoma phase 3 clinical study and released Xalost S based on the clinical study (Single Unit Dose Latanoprost Ophthalmic Solution)
    • 06. Recertified as the Innovative Pharmaceutical Company
  • 2017
    • 08. Released global first generic product, Gadobrix (Gadobutrol, MRI contrast media)
    • 05. Selected as the project of global leap technology for midsize companies
      (Ministry of Trade, Industry and Energy)
    • 02. Passed the EU-GMP recertification inspection for ophthalmic solutions
  • 2016
    • 11. Certified as the Best Company to Work (by Governor of Gyeonggi-do)
    • 11. Selected as the recepine of the industrial core technology development project grant
      (Ministry of Trade, Industry and Energy)
    • 08. Released Lamina G Plus Solution for Peptic ulcer treatment
    • 03. First export of Infreshplus Ophthalmic Solution to the EU
  • 2015
    • 11. Extended a factory building 101 (QA, QC)
    • 02. 'Released Cyporin N eye drop.
  • 2014
    • 09. 'Established a liquid formulation automatic line.
    • 01. Signed a supply agreement of Infresh plus for USA Export.
  • 2013
    • 11. CE marking approval of InfreshPlus Ophthalmic Solution.
      'Awarded Gyonggi Good Workplace.
    • 03. Yongin plant made the record of zero-disaster 15 times recording achievement (accomplishment days : 660)
      Secured an additional site for factory in Yongin (over 12500㎡ located in Buk-ri, Namsa-myeon, Yongin-si).
  • 2012
    • 06. Selected as innovative pharmaceutical firm by Ministry of Health and Welfare.
  • 2011
    • 09. Signed export contract of Xalost Plus with over 20 countries such as U.K, Switzerland etc.
    • 07. Xalost and Xalost Plus obtained GH mark as excellent health care product.
    • 03. Xalost-Designated Ministiry of Health and Welfare Columbus Project.
  • 2010
    • 03. Passed the due diligence of ANVISA in Brazil.
    • 02. Passed the due diligence of ACTIVAS in Iceland.
  • 2009
    • 11. Participated The Radiological Society of North America (RSNA) for seven consecutive years.
  • 2008
    • 06. Signed a supply agreement of Xalost Plus for EU export.
    • 02. Conducted the EU Inspection of Xalost for European market.
  • 2007
    • 09. Transferred R&D Central to the Biocenter in Gyeounggi Province.
  • 2006
    • 12. Awarded the "Excellent Management Award" of the Federation of Korean Industries.
    • 10. Ranked in 2nd place in GMP evaluation of pharmaceutical factory.
  • 2005
    • 10. Established a sales and marketing company, Accuzen, Inc., for contrast media & Adjuvant for Radiology
      Completed cGMP level plant in Yongin
    • 06. Developed generic glaucoma agent, Xalost® first in Korea.
  • 2004
    • 06. Exported contrast media products to 8 countries in Central & South America.
  • 2002
    • 10. Instituted Taejoon Ophthalmology Thesis/Service Award.
    • 07. Instituted a Taejoon Radiological Award.
  • 2001
    • 11. Awarded the "Best Small & Medium Business Corporation" in technology development section.
  • 2000
    • 06. Selected as a venture company (Seoul Regional Office Small & Medium Business Administration)
  • 1999
    • 05. Awarded the "International Trader Award" (The Ministy of Trade Industry and Energy)
    • 03. Awarded the commendation from the Minister of Commerce, Industry and Energy for the contribution to national industy.
    • 01. Received the appreciation plaque as an exemplary enterpriser of small & medium business corporation.
  • 1998
    • 12. Awarded the "Best Small & Medium Business Corporation" for productivity.
    • 11. Awarded the "Venture Business Award" from the Minister of Commerce, Industry and Energy.
  • 1995
    • 10. Received the appreciation plaque for development of diagnostic medicines (RSNA, Radiological Society of North America)
    • 09. Awarded the "Industrial Peace Award" (Yongin-si)
    • 03. Achieved localization of Contrast Media for Angiography.
  • 1994
    • 08. Awarded the "Prime Minister Citation" as an enterprise of national merit for developing national key industry.
  • 1992
    • 05. Approved establishment of central R&D corporation, appointed special military service for the company
      Approved as a company conformed to KGMP Standard (Ministry of Health & Welfare)
  • 1987
    • 04. Signed a contract for joint development & sales of the contrast media for angiography wirh Gerbet in France.
  • 1986
    • 12. Awarded the citation as an enterprise of national merit for import substitution through localization of the contrast media (Ministry of Health and Welfare)
    • 06. Signed the cooperation contract for joint development of eye drops with SANTEN Pharmaceutical Co., Ltd in Japan
      Appointed as a company with modernized facilities (Small & Medium Business Corporation)
      Developed antileprotic agent, Lapren first in Korea
  • 1985
    • 07. Selected as a promising small & medium business company (Korea Credit Guarantee Fund (KODIT))
    • 01. Became the first developer of the X-ray contrast media in Koreas, the fifth worldwide(diagnostic products)
  • 1978
    • 04. Foundation of TAEJOON Corp